Predicting Risk for Secondary Leukemia after PARPi Therapy Predicting Risk for Secondary Leukemia after PARPi Therapy
A new study pinpointed potential predictive factors for secondary myelodysplastic syndrome or acute myeloid leukemia after PARP inhibitor therapy in women with ovarian cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Hematology | Leukemia | Myelodysplastic Syndrome | Ovarian Cancer | Ovaries | Study | Women